Perioperative anxiety
Conditions
Interventions
Intervention group A:A single nasal spray of dexmedetomidine hydrochloride (dose 1.0µg/kg) 1 h prior to surgery
Intervention group B:A single nasal spray of dexmedetomidine hydrochloride (dose 1.5µg/kg) 1 h prior to surgery
Control group:At the same time point, an equal volume of saline nasal spray (placebo) was administered
Sponsors
Jingzhou Central Hospital
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age: >= 65 years old; 2. Disease diagnosis: Acute orthopedic trauma requiring surgical treatment (such as hip fractures, spinal fractures, limb fractures); 3. Preoperative anxiety: Confirmed by standardized assessment (STAI-S score >= 40 points); 4. ASA classification: I-III grade, capable of withstanding anesthesia and surgery; 5. Informed consent: The patient or legal representative signs a written informed consent form; 6. Nasal condition: No severe nasal anatomical abnormalities or acute inflammation (ensure nasal spray administration is feasible)
Exclusion criteria
Exclusion criteria: 1. Cognitive or communication disorders: such as dementia, mental illness or language impairment, making it impossible to cooperate with the assessment; 2. Drug-related contraindications: 3. History of allergy to dexmedetomidine; 4. Recent (within 72 hours) use of sedative/anxiolytic drugs (such as benzodiazepines, opioids); 5. Severe comorbidities: Uncontrolled cardiovascular diseases (such as heart rate < 50 beats per minute, systolic blood pressure < 90 mmHg); Liver and kidney dysfunction (Child-Pugh C grade or eGFR < 30 mL/min); Severe respiratory diseases (requiring mechanical ventilation or oxygen dependence); 6. Other exclusion factors: Emergency surgery (requiring immediate intervention and unable to complete the preoperative medication process); Intra-spinal anesthesia contraindications (infection at the puncture site, intracranial hypertension or severe heart and lung diseases); Long-term use of a2 receptor agonists or antagonists (such as clonidine, mivacurium);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anxiety score (STAI-S) 24h after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| hemodynamic stability;Anxiety dynamics;Security;Recovery quality;Pain control; | — |
Countries
China
Contacts
Public ContactZhang Kun
Jingzhou Central Hospital
Outcome results
None listed